trial

Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

NCTId NCT03198078
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 316 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2023-04-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
316 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2017-06-30
Primary completion
2023-04-03
Eligibility
ALL · 13 Years · 17 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)Aripiprazole

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor
H. Lundbeck A/SCollaborator

Investigators

1
Caroline Ward, PhD.Study Director

Sites

1 total
Oklahoma City, United States

Linked catalysts

1
Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy — primary completion2023-04-03

Facts & assertions

4 sourced
Enrollment
316
Phase
PHASE3
Primary Completion Date
2023-04-03
Status
COMPLETED
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
Aripiprazole
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
collaborator
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Caroline Ward, PhD.
person